托烷司琼与艾司奥美拉唑防治结直肠癌患者化疗相关胃肠道不良反应的应用研究

doi:10.3760/cma.j.issn.1007-1245.2023.18.018

摘要/Abstract

摘要：

目的　比较托烷司琼和艾司奥美拉唑对结直肠癌患者化疗相关胃肠道不良反应的防治效果。方法　选取2020年1月至2022年1月南阳市第一人民医院收治的124例结直肠癌化疗患者进行随机对照试验。采用抽签法将其分为A组和B组，各62例。A组男32例，女30例，年龄（55.25±5.37）岁。B组男31例，女31例，年龄（56.07±5.22）岁。A组应用托烷司琼配合化疗，B组应用艾司奥美拉唑配合化疗。两组均随访1年。比较两组患者化疗期间胃肠道不良反应发生情况，化疗第1、7、14天时以及1个化疗周期后恶心呕吐干呕症状评估量表（Index of Nausea，Vomiting，and Retching，INVR）评分以及远期生存质量。采用χ²检验和t检验。结果　经不同药物配合治疗后，A组化疗期间胃肠道不良反应发生率、反酸频率、恶心频率、呕吐频率均低于B组［12.90%（8/62）比30.65%（19/62）、（1.16±0.23）次/d比（3.44±1.22）次/d、（2.14±0.45）次/d比（4.41±1.23）次/d、（1.27±0.33）次/d比（3.11±1.25）次/d；χ²=5.729，t=14.461、13.647、11.207，均P<0.05］。A组化疗第1天INVR评分（20.33±5.41）分，B组（21.24±5.18）分，差异无统计学意义（t=1.272，P>0.05）；A组化疗第7、14天和化疗1个周期时INVR评分均低于B组［（15.11±3.46）分比（18.61±3.12）分、（12.33±2.46）分比（14.24±3.36）分、（10.19±1.47）分比（12.25±2.72）分；t=5.915、5.156、5.246，均P<0.05］。随访期间，A组结直肠癌患者生命质量测定量表（Functional Assessment of Cancer Therapy of Colorectal，FACT-C）中生理状况、社会/家庭状况、情感状况、功能状况、睡眠状况、依从状况维度评分均高于B组［（22.45±5.33）分比（19.35±5.31）分、（23.36±5.27）分比（20.18±5.32）分、（20.31±5.24）分比（17.25±5.33）分、（21.25±5.16）分比（18.44±5.28）分、（23.11±5.17）分比（20.21±5.22）分、（23.35±5.25）分比（20.22±5.32）分；t=3.244、3.344、3.244、2.997、3.108、3.297，均P<0.05］。结论　托烷司琼对胃肠道不良反应的防治效果均优于艾司奥美拉唑。

关键词:

结直肠癌, 化疗, 胃肠道不良反应, 托烷司琼, 艾司奥美拉唑

Abstract:

Objective　To explore the preventive and therapeutic effects of tropisetron versus esomeprazole for chemotherapy related gastrointestinal adverse reactions in patients with colorectal cancer. Methods　One hundred and twenty-four patients with colorectal cancer taking chemotherapy at Nanyang First People's Hospital from January 2020 to January 2022 were selected for the randomized controlled trial. They were divided into groups A and B by lottery, with 62 cases in each group. There were 32 males and 30 females in group A; they were (55.25±5.37) years old. There were 31 males and 31 females in group B; they were (56.07±5.22) years old. Group A took tropisetron and chemotherapy, and group B esomeprazole and chemotherapy. Both groups were followed up for one year. The incidence of gastrointestinal adverse reactions during chemotherapy, the scores of Index of Nausea, Vomiting, and Retching (INVR) on day 1, 7 and 14 of chemotherapy and after one chemotherapy cycle, and the long-term quality of life were compared between the two groups. χ² and t tests were applied. Results　After the treatment with different drugs, the incidence of gastrointestinal adverse reactions during chemotherapy, the acid reflux frequency, the nausea frequency, and the vomiting frequency in group A were lower than those in group B [12.90% (8/62) vs. 30.65% (19/62), (1.16±0.23) times/d vs. (3.44±1.22) times/d, (2.14±0.45) times/d vs. (4.41±1.23) times/d, and (1.27±0.33) times/d vs. (3.11±1.25) times/d; χ²=5.729; t=14.461, 13.647, and 11.207; all P<0.05]. There was no statistical difference in the score of INVR between groups A and B on day 1 of chemotherapy [(20.33±5.41) vs. (21.24±5.18); t=1.272, P>0.05]. The scores of INVR on day 7 and 14 of chemotherapy and after one cycle of chemotherapy in group A were lower than those in group B [(15.11±3.46) vs. (18.61±3.12), (12.33±2.46) vs. (14.24±3.36), and (10.19±1.47) vs. (12.25±2.72); t=5.915, 5.156, and 5.246; all P<0.05]. During the follow-up period, the scores of physiological status, social/family status, emotional status, functional status, sleep status, and compliance status of Functional Assessment of Cancer Therapy of Colorectal (FACT-C) in group A were higher than those in group B [(22.45±5.33) vs. (19.35±5.31), (23.36±5.27) vs. (20.18±5.32), (20.31±5.24) vs. (17.25±5.33), (21.25±5.16) vs. (18.44±5.28), (23.11±5.17) vs. (20.21±5.22), and (23.35±5.25) vs. (20.22±5.32); t=3.244, 3.344, 3.244, 2.997, 3.108, and 3.297; all P<0.05]. Conclusion　Tropisetron is better than esomeprazole in the prevention and treatment of gastrointestinal adverse reactions.

Key words:

Colorectal cancer, Chemotherapy, Gastrointestinal adverse reactions, Tropisetron, Esomeprazole

李闪珊梁冰刘其伟.

托烷司琼与艾司奥美拉唑防治结直肠癌患者化疗相关胃肠道不良反应的应用研究 [J]. 国际医药卫生导报, 2023, 29(18): 2592-2596.

Li Shanshan, Liang Bing, Liu Qiwei.

Tropisetron and esomeprazole in prevention and treatment of chemotherapy related gastrointestinal adverse reactions in patients with colorectal cancer [J]. International Medicine and Health Guidance News, 2023, 29(18): 2592-2596.

参考文献

[1] 黄鑫源,张澍田. 菌群代谢物在结直肠癌转移中作用及机制研究进展[J]. 中国老年学杂志,2023,43(3):760-763. DOI:10.3969/j.issn.1005-9202.2023.03.061.
[2] 胡晓鸣. 伊立替康及奥沙利铂联合氟尿嘧啶类药物治疗晚期结直肠癌的缓解率及安全性分析[J]. 国际医药卫生导报,2021,27(1):92-94. DOI:10.3760/cma.j.issn.1007-1245. 2021.01.024.
[3] 陈茹,刘洪伯,马丽丽. 靶向SD F-1通过调控肿瘤相关巨噬细胞亚型增强结直肠癌化疗敏感性的作用[J]. 西部医学,2023,38(1):57-64,71. DOI:10.3969/j.issn.1672-3511. 2023.01.010.
[4] 马欢,周祖邦,代九菊,等. 热消融联合肝动脉化疗栓塞治疗结直肠癌肝转移有效性和安全性的Meta分析[J]. 中国超声医学杂志,2022,38(11):1252-1255. DOI:10.3969/j.issn.1002-0101.2022.11.014.
[5] 张汉文,吴依芬,李浩,等. 结直肠癌围化疗期颊针防治奥沙利铂神经毒性及胃肠道反应的效果[J]. 广东医学,2022,43(9):1141-1144. DOI:10.13820/j.cnki.gdyx.20222648.
[6] 葛婷,周建伟,刘志勇,等. 化疗恶心呕吐治疗的研究进展[J]. 医学综述,2021,27(1):95-99. DOI:10.3969/j.issn.1006- 2084.2021.01.018.
[7] 葛婷,潘龙赐,刘志勇. 穴位敷贴结合托烷司琼治疗化疗所致恶心呕吐的临床疗效[J]. 现代肿瘤医学,2022,30(10):1870-1874. DOI:10.3969/j.issn.1672-4992.2022.10.031.
[8] 国家癌症中心中国结直肠癌筛查与早诊早治指南制定专家组. 中国结直肠癌筛查与早诊早治指南(2020,北京)[J]. 中华肿瘤杂志,2021,43(1):16-38. DOI:10.3760/cma.j.cn112152-20210105-00010.
[9] 吴秀琴,杜丽华,李慧慧,等. 结直肠癌术后化疗患者应对方式的影响因素分析[J]. 河北医药,2021,43(17):2695-2698. DOI:10.3969/j.issn.1002-7386.2021.17.033.
[10] AlFayyad I, Al-Tannir M, Howaidi J, et al. Health-related quality of life of breast and colorectal cancer patients undergoing active chemotherapy treatment: patient-reported outcomes [J]. Qual Life Res, 2022, 31(9):2673-2680. DOI: 10.1007/s11136-022-03145-8.
[11] 俞甲子,张明元,金梁斌,等. 结直肠癌不同部位的原发灶对肝转移瘤根治切除术后早期复发的影响[J]. 中华普通外科杂志,2022,37(6):434-438. DOI:10.3760/cma.j.cn113855-20211114-00655.
[12] Tachimori A, Yonemitsu K, Fukui Y, et al. Clinical significance of preoperative chemotherapy for advanced colorectal cancer [J]. Gan To Kagaku Ryoho, 2020, 47(13): 2021-2023.
[13] 张洋,杨帆,王景景. 沙利度胺联合XELOX方案化疗治疗转移性结直肠癌的疗效及对生存率的影响[J]. 癌症进展,2022,20(7):727-730. DOI:10.11877/j.issn.1672-1535. 2022.20.07.21.
[14] 曹鸣,张学彦. 质子泵抑制剂对消化系统肿瘤的双重影响[J]. 现代肿瘤医学,2022,30(4):744-748. DOI:10.3969/j.issn.1672-4992.2022.04.041.
[15] 王蓉荻,郭旭,徐孟. 敲低CTCF对5-氟尿嘧啶、顺铂耐药结直肠癌细胞恶性生物学行为的影响及其机制[J]. 山东医药,2023,63(1):42-46. DOI:10.3969/j.issn.1002- 266X. 2023.01.010.
[16] 孙博,刘丹娜,刘勋,等. 帕洛诺司琼联合地塞米松预防化疗所致恶心呕吐失败的危险因素探索[J]. 中国药房,2021,32(21):2640-2646. DOI:10.6039/j.issn.1001-0408. 2021.21.14.
[17] 于迪,龚兴瑞,张雨飞,等. 托烷司琼在止吐外作用的最新研究进展[J]. 医学研究杂志,2020(9):181-183,168. DOI:10.11969/j.issn.1673-548X.2020.09.040.
[18] 张涛,马苗苗,赵欣,等. 艾司奥美拉唑联合铝碳酸镁对比艾司奥美拉唑治疗胃溃疡疗效与安全性的Meta分析[J]. 药物流行病学杂志,2022,31(1):25-33,59. DOI:10.19960/j.cnki.issn1005-0698.2022.01.004.
[19] 黄光明,贺盛发,王希斌,等. 质子泵抑制剂预防化疗所致胃肠道反应临床效果的Meta分析[J]. 广西医科大学学报,2021,38(7):1404-1411. DOI:10.16190/j.cnki.45-1211/r.2021.07.025.
[20] 蒋梅,周岱翰,郭然,等. 姜橘暖胃膏穴位贴敷联合托烷司琼和地塞米松预防化疗所致恶心呕吐的临床疗效研究[J]. 中国全科医学,2020,23(16):2051-2056. DOI:10.12114/j.issn.1007-9572.2020.00.177.
[21] 侯晓明,权晓晓,刘杨,等. 托烷司琼联合地塞米松对乳腺癌化疗患者恶心呕吐的防治效果[J]. 癌症进展,2022,20(8):816-818,831. DOI:10.11877/j.issn.1672-1535. 2022. 20.08.15.
[22] 唐慕菲,沈芸竹,张保国. CYP2D6基因多态性对托烷司琼预防化疗所致恶心呕吐效果的影响[J]. 中国临床药理学与治疗学,2020,25(7):817-822. DOI:10.12092/j.issn.1009- 2501. 2020.07.015.
[23] 周雪莹,张策,方丽萍,等. 基于真实世界的3种止吐方案预防含顺铂多日化疗相关恶心呕吐的成本-效用分析[J]. 中国药房,2021,32(20):2509-2513. DOI:10.6039/j.issn.1001- 0408.2021.20.12.